ALDX

Aldeyra Therapeutics

Fundamental data last updated:March 2, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

-

Business Summary

Aldeyra Therapeutics is a biotechnology company focused on the discovery and development of novel therapies for immune-mediated diseases. Its primary programs target ocular and systemic inflammatory conditions.

VALUATION

P/E

-

Market Cap ($M USD)

$328

Forward P/E

17.4

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

6.7

EV / EBITDA

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.73

Next Year EPS Growth Estimate

$0.31

Next Year Revenue Growth Estimate

33.30%

Return on Equity (ROE)

-87.70%

Operating Margin

-

Debt-to-Equity

0.3

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Gainseekers Quantitative Analysis

Summary

With a market cap of $328 million, the company is currently unprofitable, posting an EPS of -$0.73 and a Return on Equity of -87.70%. However, future estimates are positive, with sales growth projected at 33.30% and an estimated EPS of $0.31 for next year. The company maintains a low debt-to-equity ratio of 0.3 and has significant institutional ownership at 65.80%.

AI Exposure / Tech Reliance

The provided financial data does not contain specific metrics regarding the company's AI exposure or technological reliance.

The Bull Case

The bull case is supported by a strong consensus rating of 1.33 and a mean target price of $9.00, with analysts forecasting 33.30% sales growth next year. Furthermore, the company is expected to achieve profitability with an estimated EPS of $0.31 next year while maintaining a low debt-to-equity ratio of 0.3.

The Bear Case

The bear case centers on current unprofitability, evidenced by an EPS of -$0.73 and a deeply negative Return on Equity of -87.70%. This skepticism is reflected in the market, where a notable 9.00% of the company's float is held in short positions.

Market Sentiment & Smart Money

Short Interest %

9.00%

Analyst Consensus

1.33

Average Analyst Price Target

$9.00

Institutional Ownership %

65.80%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low